{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:26:36Z","timestamp":1789320396741,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejso.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T10:51:33Z","timestamp":1490179893000},"page":"1134-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate \u2013 The impact of fibrosarcomatous transformation"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"P.","family":"Rutkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Klimczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"\u0141ugowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jagielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"W\u0105grodzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u0119biec-Rychter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pie\u0144kowska-Grela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"\u015awitaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2017.03.011_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00432-009-0550-3","article-title":"Current treatment options in dermatofibrosarcoma protuberans","volume":"135","author":"Lemm","year":"2009","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2017.03.011_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1586\/14737140.2015.1052799","article-title":"Current treatment options for dermatofibrosarcoma protuberans","volume":"15","author":"Rutkowski","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.ejso.2017.03.011_bib3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamadermatol.2016.1886","article-title":"Prognostic factors, treatment, and survival in dermatofibrosarcoma protuberans","volume":"152","author":"Criscito","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2017.03.011_bib4","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/DSS.0000000000000300","article-title":"Incidence and survival of primary dermatofibrosarcoma protuberans in the United States","volume":"42","author":"Kreicher","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejso.2017.03.011_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jaad.2014.03.018","article-title":"A\u00a0systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change","volume":"71","author":"Liang","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ejso.2017.03.011_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000478-199805000-00009","article-title":"Fibrosarcomatous \u2018high-grade\u2019 dermatofibrosarcoma protuberans: clinicopathological and immunohistochemical study of 41 cases with emphasis on prognostic significance","volume":"22","author":"Mentzel","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.ejso.2017.03.011_bib7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/ijc.25826","article-title":"Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib","volume":"129","author":"Stacchiotti","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2017.03.011_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2310\/7750.2014.13192","article-title":"A\u00a0clinicopathologic review of a case series of dermatofibrosarcoma protuberans with fibrosarcomatous differentiation","volume":"19","author":"Kuzel","year":"2015","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.ejso.2017.03.011_bib9","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1200\/JCO.2005.02.5122","article-title":"Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate","volume":"23","author":"Fiore","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2017.03.011_bib10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/archdermatol.2012.1440","article-title":"Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review","volume":"148","author":"Foroozan","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejso.2017.03.011_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(02)00848-8","article-title":"Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: dermatofibrosarcoma protuberans and giant cell fibroblastoma","volume":"140","author":"Sandberg","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.ejso.2017.03.011_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.10202","article-title":"Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment","volume":"37","author":"Sirvent","year":"2003","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ejso.2017.03.011_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0197-95","article-title":"Deregulation of the platelet derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma","volume":"15","author":"Simon","year":"1997","journal-title":"Nat Gen"},{"issue":"1","key":"10.1016\/j.ejso.2017.03.011_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00000478-200301000-00004","article-title":"Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data\u2013a study from the French Federation of Cancer Centers Sarcoma Group","volume":"27","author":"Terrier-Lacombe","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejso.2017.03.011_bib15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.2005.07.088","article-title":"Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib Target Exploration Consortium Study B2225","volume":"23","author":"McArthur","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2017.03.011_bib16","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2017.03.011_bib17","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.2009.25.7899","article-title":"Imatinib mesylate in advanced dermatofibrosarcoma protuberans (DFSP): pooled analysis of two phase II clinical trials","volume":"28","author":"Rutkowski","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2017.03.011_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1468-3083.2010.03774.x","article-title":"Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection","volume":"25","author":"Rutkowski","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ejso.2017.03.011_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2017.03.011_bib20","series-title":"Dermatofibrosarcoma protuberans","author":"NCCN Guidelines v. 1","year":"2016"},{"issue":"17","key":"10.1016\/j.ejso.2017.03.011_bib21","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ejca.2015.06.108","article-title":"Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline","volume":"51","author":"Saiag","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2017.03.011_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00001813-200504000-00014","article-title":"Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate","volume":"16","author":"Labropoulos","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejso.2017.03.011_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2133.2004.06024.x","article-title":"Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans","volume":"151","author":"Mizutani","year":"2004","journal-title":"Br J Dermatol"},{"issue":"17","key":"10.1016\/j.ejso.2017.03.011_bib24","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.1097\/MD.0000000000000773","article-title":"Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine"},{"issue":"17","key":"10.1016\/j.ejso.2017.03.011_bib25","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2169\/internalmedicine.55.6836","article-title":"Effectiveness of imatinib mesylate treatment in a patient with dermatofibrosarcoma protuberans with pulmonary and pancreatic metastases","volume":"55","author":"Tatai","year":"2016","journal-title":"Intern Med"},{"issue":"15_suppl","key":"10.1016\/j.ejso.2017.03.011_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.10593","article-title":"Response to imatinib mesylate (IM) in fibrosarcoma (FS) arising in dermatofibrosarcoma protuberans (DFSP)","volume":"26","author":"Gronchi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2017.03.011_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-15-1243","article-title":"Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP)","volume":"22","author":"Stacchiotti","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejso.2017.03.011_bib28","first-page":"261","article-title":"Risk factors for distant metastasis of dermatofibrosarcoma protuberans","volume":"17","author":"Hayakawa","year":"2016","journal-title":"J\u00a0Orthop Traumatol"},{"key":"10.1016\/j.ejso.2017.03.011_bib29","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-09-3401","article-title":"Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients","volume":"16","author":"K\u00e9rob","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2017.03.011_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-13-1411","article-title":"Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up","volume":"20","author":"Ugurel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2017.03.011_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10006-008-0130-8","article-title":"Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans\u2013a case report","volume":"12","author":"Lemm","year":"2008","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.ejso.2017.03.011_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/archdermatol.2009.140","article-title":"Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans","volume":"145","author":"Han","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejso.2017.03.011_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1477-7819-11-59","article-title":"Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib","volume":"11","author":"Wicherts","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2017.03.011_bib34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.6004\/jnccn.2010.0065","article-title":"Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses","volume":"8","author":"Johnson-Jahangir","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ejso.2017.03.011_bib35","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1158\/1535-7163.MCT-14-0793","article-title":"CDKN2A\/p16 loss implicates CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans","volume":"14","author":"Eilers","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejso.2017.03.011_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jid.2016.06.634","article-title":"Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment","volume":"137","author":"Tazzari","year":"2017","journal-title":"J\u00a0Investig. Dermatol"},{"key":"10.1016\/j.ejso.2017.03.011_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1245\/s10434-010-1316-5","article-title":"Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy","volume":"18","author":"Fields","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2017.03.011_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-3-5","article-title":"Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report","volume":"3","author":"Kamar","year":"2013","journal-title":"Clin Sarcoma Res"},{"issue":"5","key":"10.1016\/j.ejso.2017.03.011_bib39","first-page":"8288","article-title":"Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib","volume":"8","author":"Fu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ejso.2017.03.011_bib40","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2007.14.7330","article-title":"Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans","volume":"26","author":"Kerob","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2017.03.011_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.humpath.2007.06.009","volume":"39","author":"Patel","year":"2008","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ejso.2017.03.011_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/jcp.2006.037200","article-title":"Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas","volume":"60","author":"Szollosi","year":"2007","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.ejso.2017.03.011_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.semdp.2012.01.002","article-title":"Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management","volume":"30","author":"Llombart","year":"2013","journal-title":"Semin Diagn Pathol"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317304225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317304225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:20:18Z","timestamp":1535952018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798317304225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0748798317304225"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2017.03.011","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate \u2013 The impact of fibrosarcomatous transformation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}